RxDoctor Payments Data

Margaret Hoffmeyer, MD

Family Medicine · Florence, SCNPI 1215962568

Payments from drug & device makers

$1,580in general payments, 2019–2025

Across 89 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$763
  • Merck$206
  • Astellas Pharma US Inc$122
  • Johnson & Johnson$109
  • AstraZeneca$71
  • Lilly USA, LLC$66
  • plus $241 from 8 others

What the payments were for

  • Food & beverage$1,54798%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,580 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$125,907
Medicare patients
291
Services billed
1,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide66$124,509
MounjaroTirzepatide78$89,377
EliquisApixaban62$61,613
JardianceEmpagliflozin57$56,341
OzempicSemaglutide36$50,760
LinzessLinaclotide28$34,272
XareltoRivaroxaban27$34,080
EntrestoSacubitril/Valsartan25$32,633
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$30,557
JanuviaSitagliptin Phosphate33$29,206
MyrbetriqMirabegron16$18,635
Breo ElliptaFluticasone/Vilanterol25$9,755
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen248$7,557
Repatha SyringeEvolocumab12$6,328
Rosuvastatin Calcium305$5,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$763$175,269102 claims
Lilly USA, LLCMounjaro$66$89,37778 claims
AbbVieLinzess, Synthroid$26$38,64672 claims
Johnson & JohnsonXarelto$109$34,08027 claims
NovartisEntresto$28$32,63325 claims
MerckJanuvia$206$29,20633 claims
Astellas Pharma US IncMyrbetriq$122$18,63516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →